Medicare AdvantageCoverageMedium impact
MA06.001g, Apheresis Therapy
Independence Blue Cross·Hematology, Oncology, Nephrology +1 more·Medical Policy
Effective date
Jun 8, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.001g for Apheresis Therapy is being updated with changes to coverage position and medical necessity criteria. This affects how apheresis procedures will be covered and what documentation will be required for reimbursement.
Action Required
Before June 8, 2026: Billing team must review updated MA06.001g policy for apheresis therapy coverage and medical necessity criteria changes. Update prior authorization workflows and documentation requirements for apheresis procedures. Ensure providers are aware of new medical necessity criteria to prevent claim denials.